SCHEMBL22200540

SCHEMBL22200540

CC(C)n1c(=O)c(-c2ccc(N[S+]([O-])Cc3ccccc3)c(F)c2F)nc2cnc(N[C@H]3CC(F)CN(C(=O)OCc4ccccc4)C3)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.39
LCK P06239 1/20 0.32
EGFR P00533 3/20 0.31
CDK2 P24941 2/20 0.31
CDK1 P06493 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
GRIN2B Q13224 1/20 0.31
MAPK8 P45983 3/20 0.30
MAPK9 P45984 3/20 0.30
MAPK10 P53779 3/20 0.30
CCNK O75909 1/20 0.30
CCNA2 P20248 1/20 0.30
CDK7 P50613 1/20 0.30
CCNH P51946 1/20 0.30
MNAT1 P51948 1/20 0.30
CDK12 Q9NYV4 1/20 0.30
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200539 0.88 ERN1 (0.51) ERN1EGFRCDK2
SCHEMBL29353878 0.88 ERN1 (0.51) ERN1EGFRCDK2
SCHEMBL22200542 0.81 ERN1 (0.46) ERN1CDK2CDK1CDK4CCND1
SCHEMBL29356361 0.81 ERN1 (0.46) ERN1CDK2CDK1CDK4CCND1
SCHEMBL22200720 0.81 HDAC3 (0.38) ERN1LCKEGFRCDK2CDK1
SCHEMBL29354891 0.81 HDAC3 (0.38) ERN1LCKEGFRCDK2CDK1
SCHEMBL22190581 0.80 ERN1 (0.53) ERN1EGFRCDK2MAPK8MAPK9
SCHEMBL29356760 0.80 ERN1 (0.48) ERN1CDK2CDK1CDK4CCND1
SCHEMBL22200705 0.80 ERN1 (0.48) ERN1CDK2CDK1CDK4CCND1
SCHEMBL22200342 0.79 ERN1 (0.63) ERN1EGFRCDK2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed